Mouse Anti-Rat CD161 Antibody (S-R628)

產(chǎn)品型號：S0B5101

更新時(shí)間：2025-10-08

廠商性質(zhì)：生產(chǎn)廠家

訪問量：88

服務(wù)熱線

15855403091

立即咨詢

產(chǎn)品分類

PRODUCT CLASSIFICATION

抗體/抗原

ELISA試劑盒抗體試劑盒二抗試劑盒二抗其它流式抗體瓊脂糖/磁珠偶聯(lián)抗體抗Payload抗體泛修飾抗體標(biāo)簽/內(nèi)參抗體功能性抗體 Biosimilar抗體偶聯(lián)抗體配對抗體病理/IHC抗體

查看全部產(chǎn)品

相關(guān)文章

乳腺病理免疫組化解碼：從標(biāo)記物判讀到陷阱規(guī)避全指南

成纖維細(xì)胞生長因子-1（FGF1）如何重編程疾病命運(yùn)與國自然研究新范式

大鼠免疫球蛋白的免疫功能及應(yīng)用價(jià)值

視黃醇結(jié)合蛋白4（RBP4）抗體：發(fā)掘其在疾病風(fēng)險(xiǎn)中的診斷潛力

產(chǎn)品介紹

CD161, also known as KLRB1 or NKRP1A, is a C-type lectin-like receptor primarily expressed on the surface of natural killer （NK） cells and a subset of T cells, including mucosal-associated invariant T （MAIT） cells and some CD8+ T cells. It is particularly enriched in immune cells located in mucosal sites such as the gut and liver. CD161 binds to its ligand, lectin-like transcript 1 （LLT1, also known as CLEC2D）, and this interaction can have both inhibitory and costimulatory effects on immune cells. In the context of cancer immunotherapy, CD161 has been identified as a potential inhibitory receptor in glioma-infiltrating T cells. Its activation by CLEC2D on tumor or immunosuppressive cells can dampen T cell responses against cancer cells. Recent studies suggest that blocking the CD161-CLEC2D interaction may enhance T cell-mediated antitumor activity, making CD161 a promising target for cancer immunotherapy.

上一個(gè)：S0B5102Rat Anti-Mouse CD1d Antibody (S-R665)